Loading

Oregon Bulletin

May 1, 2011

Oregon Board of Naturopathic Medicine
Chapter 850

  • Rule Caption: Rule on reapplication of license when license has been disciplined.
  • Adm. Order No.: OBNM 1-2011
  • Filed with Sec. of State: 4-12-2011
  • Certified to be Effective: 4-12-11
  • Notice Publication Date: 3-1-2011
  • Rules Adopted: 850-050-0200
  • Subject: 850-050-0200 Reapplication
  •       An applicant, licensee or certificate holder whose application for license or certificate, or whose license or certificate, has been denied or revoked, or who voluntarily surrendered the application for license or certificate, or the license or certificate, may not reapply for a minimum period of three years; unless otherwise stated in a Board order denying or revoking or accepting a voluntary surrender of he application, license or certificate.
  • Rules Coordinator: Anne Walsh—(971) 673-0193
  •  
  • 850-050-0200
  • Reapplication
  • An applicant, licensee or certificate holder whose application for license or certificate, or whose license or certificate, has been denied or revoked, or who voluntarily surrendered the application for license or certificate, or the license or certificate, may not reapply for a minimum period of three years; unless otherwise specified in a Board order denying or revoking or accepting a voluntary surrender of the application, license or certificate.
  • Stat. Auth.: ORS 685.125
  • Stats. Implemented: ORS 685.110
  • Hist.: OBNM 1-2011, f. & cert. ef. 4-12-11
  •  
  • Rule Caption: Rule removes the reference to the AHFS 2009 which is no longer relevant.
  • Adm. Order No.: OBNM 2-2011
  • Filed with Sec. of State: 4-12-2011
  • Certified to be Effective: 4-12-11
  • Notice Publication Date: 3-1-2011
  • Rules Amended: 850-060-0225, 850-060-0226
  • Subject: Rule removes reference to AFHS, which was used as a guidance to establish formulary classifications.
  • Rules Coordinator: Anne Walsh—(971) 673-0193
  •  
  • 850-060-0225
  • Formulary Compendium
  • The Formulary Council has approved the following substances; in addition to the pharmacologic-therapeutic classifications listed in 850-060-0226. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.
  • (1) Abacavir;
  • (2) Acarbose;
  • (3) Acetic Acid;
  • (4) Acetylcysteine;
  • (5) Acitretin;
  • (6) Acyclovir;
  • (7) Adapalene;
  • (8) Adenosine Monophosphate;
  • (9) Albuterol Sulfate;
  • (10) Alendronate;
  • (11) Allopurinol;
  • (12) Alprostadil;
  • (13) Amantadine;
  • (14) Amino Acids;
  • (15) Amino Aspirins;
  • (16) Aminoglycosides;
  • (17) Aminolevulinic Acid;
  • (18) Aminophylline;
  • (19) Aminosalicylic Acid;
  • (20) Ammonium Chloride;
  • (21) Ammonium lactate lotion 12%;
  • (22) Amoxicillin;
  • (23) Amoxicillin & Clavulanate;
  • (24) Amphotericin B;
  • (25) Ampicillin;
  • (26) Ampicillin & Sulbactam;
  • (27) Anastrozole;
  • (28) Anthralin;
  • (29) Atorvastatin;
  • (30) Atropine;
  • (31) Atropine Sulfate;
  • (32) Auranofin;
  • (33) Azelaic Acid;
  • (34) Azithromycin;
  • (35) Bacampicillin;
  • (36) Bacitracin;
  • (37) Baclofen;
  • (38) Becaplermin;
  • (39) Belladonna;
  • (40) Benazepril;
  • (41) Benzodiazepines;
  • (42) Benzoic Acid;
  • (43) Benzonatate;
  • (44) Betaine;
  • (45) Betamethasone;
  • (46) Bethanechol Chloride;
  • (47) Bichloracetic Acid*;
  • (48) Bimatoprost Solution 0.03%;
  • (49) Biologicals;
  • (50) Bisphosphonates;
  • (51) Bromocriptine;
  • (52) Budesonide;
  • (53) Buprenorphine;
  • (54) Butorphanol;
  • (55) Cabergoline;
  • (56) Calcipotriene;
  • (57) Calcitonin;
  • (58) Calcitriol;
  • (59) Carbamide Peroxide;
  • (60) Carbidopa;
  • (61) Carbol-Fuchsin;
  • (62) Captopril;
  • (63) Cefaclor;
  • (64) Cefdinir;
  • (65) Cefibuten;
  • (66) Cefadroxil;
  • (67) Cefditoren;
  • (68) Cefixime;
  • (69) Cefonicid Sodium;
  • (70) Cefpodoxime Proxetil;
  • (71) Cefprozil;
  • (72) Ceftibuten;
  • (73) Cefuroxime;
  • (74) Celecoxib;
  • (75) Cellulose Sodium Phosphate;
  • (76) Cenestin;
  • (77) Cephalexin;
  • (78) Cephradine;
  • (79) Chirocaine*;
  • (80) Chloramphenicol;
  • (81) Chloroquine;
  • (82) Citrate Salts;
  • (83) Clarithromycin;
  • (84) Clindamycin;
  • (85) Clioquinol;
  • (86) Clostridium botulinum toxin (ab);
  • (87) Cloxacillin;
  • (88) Codeine;
  • (89) Colchicine;
  • (90) Colistimethate;
  • (91) Collagenase;
  • (92) Condylox;
  • (93) Cortisone;
  • (94) Coumadin;
  • (95) Cromolyn Sodium;
  • (96) Cyanocobalamin;
  • (97) Cycloserine;
  • (98) Cytisine
  • (99) Danazol;
  • (100) Deferoxamine/Desferroxamine (Board approved certification required before therapeutic IV chelation is allowed);
  • (101) Demeclocycline Hydrochloride;
  • (102) Desmopressin;
  • (103) Desoxyribonuclease;
  • (104) Dexamethasone;
  • (105) Dextran;
  • (106) Dextromethorphan;
  • (107) Dextrose;
  • (108) Dextrothyroxine;
  • (109) Diclofenac;
  • (110) Dicloxacillin;
  • (111) Dihydroergotamine Migranal;
  • (112) Didanosine;
  • (113) Dimethyl Sulfone (DMSO);
  • (114) Digitalis;
  • (115) Digitoxin;
  • (116) Digoxin;
  • (117) Dinoprostone;
  • (118) Diphenhydramine
  • (119) Diphylline;
  • (120) Dirithromycin;
  • (121) DMPS (Board approved certification required before therapeutic IV chelation is allowed);
  • (122) DMSA;
  • (123) Doxercalciferol;
  • (124) Doxycycline;
  • (125) Dronabinol;
  • (126) Dyclonine;
  • (127) EDTA (Board approved certification required before therapeutic IV chelation is allowed);
  • (128) Electrolyte Solutions;
  • (129) Emtricitabine;
  • (130) Enalapril;
  • (131) Ephedrine;
  • (132) Epinephrine*;
  • (133) Epinephrine (auto-inject);
  • (134) Ergoloid Mesylates;
  • (135) Ergonovine Maleate;
  • (136) Ergotamine;
  • (137) Erythromycins;
  • (138) Erythropoietin;
  • (139) Estradiol;
  • (140) Estriol;
  • (141) Estrogen-Progestin Combinations;
  • (142) Estrogens, Conjugated;
  • (143) Estrogen, Esterified;
  • (144) Estrone;
  • (145) Estropipate;
  • (146) Eszopiclone;
  • (147) Ethyl Chloride;
  • (148) Etidronate;
  • (149) Etodolac;
  • (150) Exenatide;
  • (151) Ezetimibe;
  • (152) Famciclovir;
  • (153) Fentanyl;
  • (154) Fibrinolysin;
  • (155) Flavoxate;
  • (156) Fluconazole;
  • (157) Fludrocortisone Acetate;
  • (158) Flunisolide;
  • (159) Fluorides;
  • (160) Fluoroquinolones;
  • (161) Fluoroquinolines;
  • (162) Fluorouracil;
  • (163) Fluticasone propionate;
  • (164) Fluvastatin;
  • (165) Fosinopril;
  • (166) Gaba Analogs;
  • (167) Gabapentin;
  • (168) Galantamine H. Br.;
  • (169) Gamma-Hydroxy Butyrate;
  • (170) Ganciclovir;
  • (171) Gentamicin;
  • (172) Gentian Violet;
  • (173) Glycerin/Glycerol;
  • (174) Griseofulvin;
  • (175) Guaifenesin;
  • (176) Heparin — subcutaneous, sublingual and heparin locks;
  • (177) Hexachlorophene;
  • (178) Homatropine Hydrobromide*;
  • (179) Human Growth Hormone;
  • (180) Hyaluronic Acid;
  • (181) Hyaluronidase;
  • (182) Hydrocodone;
  • (183) Hydrocortisone;
  • (184) Hydrogen Peroxide;
  • (185) Hydromorphone;
  • (186) Hydroquinone;
  • (187) Hydroxychloroquine;
  • (188) Hydroxypolyethoxydodecane*;
  • (189) Hyoscyamine;
  • (190) Iloprost Inhalation Solution;
  • (191) Imiquimod Cream (5%);
  • (192) Immune Globulins*;
  • (193) Indomethacin;
  • (194) Insulin;
  • (195) Interferon Alpha b w/Ribaviron;
  • (196) Iodine;
  • (197) Iodoquinol;
  • (198) Iron Preparations;
  • (199) Isosorbide Dinitrate;
  • (200) Isotretinoin;
  • (201) Itraconazole;
  • (202) Kanamycin Sulfate;
  • (203) Ketoconazole;
  • (204) Ketorolac;
  • (205) Lactulose;
  • (206) Lamivudine;
  • (207) Letrozole;
  • (208) Leucovorin Calcium;
  • (209) Levalbuteral;
  • (210) Levocarnitine;
  • (211) Levodopa;
  • (212) Levonorgestrel;
  • (213) Levorphanol;
  • (214) Levothyroxine;
  • (215) Lincomycin;
  • (216) Lindane;
  • (217) Liothyronine;
  • (218) Liotrix;
  • (219) Lisinopril;
  • (220) Lisuride;
  • (221) Lithium;
  • (222) Lovastatin;
  • (223) Mebendazole;
  • (224) Meclizine;
  • (225) Medroxyprogesterone;
  • (226) Medrysone;
  • (227) Mefloquine;
  • (228) Megestrol Acetate;
  • (229) Meloxicam;
  • (230) Memantine;
  • (231) Mercury, Ammoniated;
  • (232) Mesalamine;
  • (233) Metformin;
  • (234) Methadone;
  • (235) Methimazole;
  • (236) Methoxsalen;
  • (237) Methscopolamine;
  • (238) Methylergonovine;
  • (239) Methylprednisolone;
  • (240) Methylsulfonylmethane (MSM);
  • (241) Methyltestosterone;
  • (242) Methysergide;
  • (243) Metronidazole;
  • (244) Miglitol;
  • (245) Minerals (Oral & Injectable);
  • (246) Minocycline;
  • (247) Misoprostol;
  • (248) Moexipril;
  • (249) Monobenzone;
  • (250) Morphine;
  • (251) Mupirocin;
  • (252) Nafarelin acetate;
  • (253) Naloxone;
  • (254) Naltrexone;
  • (255) Natamycin;
  • (256) Nateglinide;
  • (257) Nicotine;
  • (258) Nitroglycerin;
  • (259) Novobiocin;
  • (260) Nystatin;
  • (261) Olsalazine;
  • (262) Omeprazole;
  • (263) Opium;
  • (264) Over the Counter (OTC)
  • (265) Oxacillin;
  • (266) Oxamniquine;
  • (267) Oxaprozin;
  • (268) Oxtriphylline;
  • (269) Oxycodone;
  • (270) Oxygen;
  • (271) Oxymorphone;
  • (272) Oxytetracycline;
  • (273) Oxytocin*;
  • (274) Pancrelipase;
  • (275) Papain;
  • (276) Papavarine;
  • (277) Paramethasone;
  • (278) Paregoric;
  • (279) Penciclovir;
  • (280) Penicillamine (Board approved certification required before therapeutic IV chelation is allowed);
  • (281) Penicillin;
  • (282) Pentosan;
  • (283) Pentoxifylline;
  • (284) Pergolide;
  • (285) Perindopril;
  • (286) Permethrin;
  • (287) Peroxicam;
  • (288) Phenazopyridine;
  • (289) Phenylalkylamine;
  • (290) Phenylephrine*;
  • (291) Physostigmine;
  • (292) Pilocarpine;
  • (293) Pimecrolimus Cream 1%;
  • (294) Piperazine Citrate;
  • (295) Podophyllum Resin;
  • (296) Polymyxin B Sulfate;
  • (297) Polysaccharide-Iron Complex;
  • (298) Potassium Iodide;
  • (299) Potassium Supplements;
  • (300) Pramoxine;
  • (301) Pravastatin;
  • (302) Praziquantel;
  • (303) Prednisolone;
  • (304) Prednisone;
  • (305) Pregabalin;
  • (306) Progesterone;
  • (307) Progestins;
  • (308) Propionic Acids;
  • (309) Propylthiouracil;
  • (310) Prostaglandins;
  • (311) Proton Pump inhibitor;
  • (312) Pseudoephedrine;
  • (313) Pyrazinamide;
  • (314) Pyrethrins;
  • (315) Quinapril;
  • (316) Quinidine;
  • (317) Quinilones;
  • (318) Quinine Sulfate;
  • (319) Quinines;
  • (320) Quinolines;
  • (321) Ramopril;
  • (322) Rauwolfia Alkaloids;
  • (323) Rho(D) Immune globulins*;
  • (324) Rifabutin;
  • (325) Rifampin;
  • (326) Rimantidine;
  • (327) Risendronate;
  • (328) Ranolazine;
  • (329) Salicylamide;
  • (330) Salicylate Salts;
  • (331) Salicylic Acid;
  • (332) Salsalate;
  • (333) Scopolamine;
  • (334) Selegiline;
  • (335) Selenium Sulfide;
  • (336) Sildenafil Citrate;
  • (337) Silver Nitrate;
  • (338) Simvastatin;
  • (339) Sitagliptin;
  • (340) Sodium Polystyrene Sulfonate;
  • (341) Sodium Tetradecyl Sulfate
  • (342) Sodium Thiosulfate;
  • (343) Spironolactone;
  • (344) Stavudine;
  • (345) Spectinomycin;
  • (346) Sucralfate;
  • (347) Sulfasalazine;
  • (348) Sulfonamide/Trimethoprim/Sulfones;
  • (349) Sulindac;
  • (350) Tacrolimus;
  • (351) Tazarotene topical gel;
  • (352) Telithromycin;
  • (353) Tenofovir;
  • (354) Testosterone;
  • (355) Tetracycline;
  • (356) Theophylline;
  • (357) Thiabendazole;
  • (358) Thyroid;
  • (359) Thyroxine;
  • (360) Tiagabine;
  • (361) Tibolone;
  • (362) Tiludronate;
  • (363) Tinidazole;
  • (364) Tobramycin;
  • (365) Tolmetin;
  • (366) Topical steroids;
  • (367) Tramadol;
  • (368) Trandolapril;
  • (369) Trazodone;
  • (370) Tretinoin;
  • (371) Triamcinolone;
  • (372) Triamterene;
  • (373) Trichloracetic Acid*;
  • (374) Trimetazidine;
  • (375) Trioxsalen;
  • (376) Triptans;
  • (377) Troleandomycin;
  • (378) Undecylenic Acid;
  • (379) Urea;
  • (380) Urised;
  • (381) Ursodiol;
  • (382) Valacyclovir;
  • (383) Valproic Acid;
  • (384) Vancomycin;
  • (385) Varenicline;
  • (386) Verapamil;
  • (387) Verdenafil HCL;
  • (388) Vidarabine;
  • (389) Vitamins (Oral & Injectable);
  • (390) Yohimbine;
  • (391) Zalcitabine;
  • (392) Zidovudine;
  • (393) Zolpidem;
  • (394) Local Anesthetics:
  • (a) Benzocaine*;
  • (b) Bupivacaine*;
  • (c) Chloroprocaine*;
  • (d) Dyclonine*;
  • (e) Etidocaine*;
  • (f) Lidocaine*;
  • (g) Lidocaine (non-injectable dosage form);
  • (h) Mepivocaine*;
  • (i) Prilocaine*;
  • (j) Procaine*;
  • (k) Tetracaine*.
  • (395) Vaccines:
  • (a) BCG*;
  • (b) Cholera*;
  • (c) Diptheria*;
  • (d) DPT*;
  • (e) Haemophilus b Conjugate*;
  • (f) Hepatitis A Virus*;
  • (g) Hepatitis B*;
  • (h) Influenza Virus*;
  • (i) Japanese Encephalitis Virus*;
  • (j) Measles Virus*;
  • (k) Mumps Virus*;
  • (l) Pertussis*;
  • (m) Plague*;
  • (n) Pneumococcal*;
  • (o) Poliovirus Inactivated*;
  • (p) Poliovirus-Live Oral*;
  • (q) Rabies*;
  • (r) Rubella*;
  • (s) Smallpox*;
  • (t) Tetanus IG*;
  • (u) Tetanus Toxoid*;
  • (v) Typhoid*;
  • (w) Varicella*;
  • (x) Yellow Fever*;
  • (396) SkinTests:
  • (a) Diptheria*;
  • (b) Mumps*;
  • (c) Tuberculin*.
  • Stat. Auth.: ORS 685.125
  • Stats. Implemented: ORS 681.145
  • Hist.: NE 2-1990, f. & cert. ef. 11-8-90; NE 1-1997, f. 10-13-97, cert. ef. 10-20-97; BNE 1-1999, f. 6-24-99, cert. ef. 6-25-99; BNE 1-2000, f. & cert. ef. 1-10-00; BNE 3-2000, f. & cert. ef. 8-16-00; BNE 2-2001, f. & cert. ef. 2-7-01; BNE 4-2001, f. & cert. ef. 5-25-01; BNE 8-2001, f. & cert. ef. 12-7-01; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; BNE 3-2005, f. & cert. ef. 2-4-05; BNE 5-2005, f. & cert. ef. 6-10-05; Renumbered from 850-010-0225, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 2-2011, f. & cert. ef. 4-12-11
  •  
  • 850-060-0226
  • Formulary Compendium Classifications
  • The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.
  • (1) Antihistamine Drugs;
  • (a) First Generation Antihistamine Drugs;
  • (A) Ethanolamine Derivatives;
  • (B) Ethylenediamine Derivatives;
  • (C) Phenothiazine Derivatives;
  • (D) Piperazine Derivatives;
  • (E) Propylamine Derivatives;
  • (F) Miscellaneous Derivatives;
  • (b) Second Generation Antihistamines;
  • (2) Anti-Infective Agents;
  • (a) Antihelmintics;
  • (b) Antibacterials;
  • (A) Aminoglycosides;
  • (B) Cephalosporins;
  • (i) First Generation Cephalosporins;
  • (ii) Second Generation Cephalosporins;
  • (iii) Third Generation Cephalosporins;
  • (iv) Fourth Generation Cephalosporins;
  • (C) Miscellaneous β-Lactams;
  • (i) Carbacephems;
  • (ii) Carbapenems;
  • (iii) Cephamycins;
  • (iv) Monobactams;
  • (D) Chloramphenicol;
  • (E) Macrolides;
  • (i) Erythromycins;
  • (ii) Ketolides;
  • (iii) Other Macrolides;
  • (F) Penicillins;
  • (i) Natural Penicillins;
  • (ii) Aminopenicillins;
  • (iii) Penicillinase-resistant Penicillins;
  • (iv) Extended-spectrum Penicillins;
  • (G) Quinolones;
  • (H) Sulfonamides;
  • (I) Tetracyclines;
  • (i) Glycylcyclines;
  • (J) Antibacterials, Miscellaneous;
  • (i) Aminocyclitols;
  • (ii) Bacitracins;
  • (iii) Cyclic Lipopeptides;
  • (iv) Glycopeptides;
  • (v) Lincomycins;
  • (vi) Oxazolidinones;
  • (vii) Polymyxins;
  • (viii) Rifamycins
  • (ix) Streptogramins;
  • (c) Antifungals;
  • (A) Allylamines;
  • (B) Azoles;
  • (C) Echinocandins;
  • (D) Polyenes;
  • (E) Pyrimidines;
  • (F) Antifungals, Miscellaneous;
  • (d) Antimycobacterials;
  • (A) Antituberculosis Agents;
  • (B) Antimycobacterials, Miscellaneous;
  • (e) Antivirals;
  • (A) Adamantanes;
  • (B) Antiretrovirals;
  • (i) HIV Fusion Inhibitors;
  • (ii) HIV Protease Inhibitors;
  • (iii) Integrase Inhibitors;
  • (iv) Nonnucleoside Reverse Transcriptase Inhibitors;
  • (v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors;
  • (C) Interferons;
  • (D) Monoclonal Antibodies;
  • (E) Neuraminidase Inhibitors;
  • (F) Nucleosides and Nucleotides;
  • (G) Antivirals, Miscellaneous;
  • (f) Antiprotozoals;
  • (A) Amebicides;
  • (B) Antimalarials;
  • (C) Antiprotozoals, Miscellaneous;
  • (3) Antineoplastic Agents (oral and topical only) limited to the following:
  • (a) 5FU;
  • (b) Anastrozole;
  • (c) Letrozole;
  • (d) Megestrol;
  • (e) Mercaptopunne;
  • (f) Methotrexate;
  • (g) Tamoxifen;
  • (h) Tretinoin;
  • (4) Autonomic Drugs;
  • (a) Parasympathomimetic (Cholinergic) Agents;
  • (b) Anticholinergic Agents;
  • (A) Antimuscarinics/ Antispasmodics;
  • (c) Sympathomimetic (Adrenergic) Agents;
  • (A) α-Adrenergic Agonists;
  • (B) β- Adrenergic Agonists;
  • (i) Non-selective β- Adrenergic Agonists;
  • (ii) Selective β1- Adrenergic Agonists;
  • (iii) Selective β2- Adrenergic Agonists;
  • (C) α-And β-Adrenergic Agonists;
  • (d) Sympatholytic (Adrenergic Blocking) Agents;
  • (e) Skeletal Muscle Relaxants;
  • (A) Centrally Acting Skeletal Muscle Relaxants;
  • (B) Direct-acting Skeletal Muscle Relaxants;
  • (C) GABA-derivative Skeletal Muscle Relaxants;
  • (D) Neuromuscular Blocking Agents;
  • (E) Skeletal Muscle Relaxants, Miscellaneous;
  • (f) Autonomic Drugs, Miscellaneous;
  • (5) Blood Derivatives;
  • (6) Blood Formation, Coagulation, and Thrombosis;
  • (a) Antianemia Drugs;
  • (A) Iron Preparations;
  • (b) Antithrombotic Agents;
  • (A) Anticoagulants;
  • (i) Coumarin Derivatives;
  • (ii) Direct Thrombin Inhibitors;
  • (iii) Heparins;
  • (iv) Anticoagulants, Miscellaneous;
  • (c) Platelet-reducing Agents;
  • (d) Platelet-aggregation Inhibitors;
  • (e) Thrombolytic Agents;
  • (f) Hematopoietic Agents;
  • (g) Hemorrheologic Agents;
  • (h) Antihemorrhagic Agents;
  • (A) Antiheparin Agents;
  • (B) Hemostatics;
  • (7) Cardiovascular Drugs;
  • (a) Cardiac Drugs;
  • (A) Antiarrhythmic Agents;
  • (i) Class Ia Antiarrhythmics;
  • (ii) Class Ib Antiarrhythmics;
  • (iii) Class Ic Antiarrhythmics;
  • (iv) Class III Antiarrhythmics;
  • (v) Class IV Antiarrhythmics;
  • (B) Cardiotonic Agents;
  • (C) Cardiac Drugs, Miscellaneous;
  • (b) Antilipemic Agents;
  • (A) Bile Acid Sequestrants;
  • (B) Cholesterol Absorption Inhibitors;
  • (C) Fibric Acid Derivatives;
  • (D) HMG-CoA Reductase Inhibitors;
  • (E) Antilipemic Agents, Miscellaneous;
  • (c) Hypotensive Agents;
  • (A) Calcium-Channel Blocking Agents;
  • (B) Central a-Agonists;
  • (C) Direct Vasodilators;
  • (D) Peripheral Adrenergic Inhibitors;
  • (d) Vasodilating Agents;
  • (A) Nitrates and Nitrites;
  • (B) Phosphodiesterase Inhibitors;
  • (C) Vasodilating Agents, Miscellaneous;
  • (e) Sclerosing Agents;
  • (f) α-Adrenergic Blocking Agents;
  • (g) β-Adrenergic Blocking Agents;
  • (h) Calcium-Channel Blocking Agents;
  • (A) Dihydropyridines;
  • (B) Calcium-Channel Blocking Agents, Miscellaneous;
  • (i) Renin-Angiotensin-Aldosterone System Inhibitors;
  • (A) Angiotensin-Converting Enzyme Inhibitors;
  • (B) Angiotensin II Receptor Antagonists;
  • (C) Mineralocorticoid (Aldosterone) Receptor Antagonists;
  • (D) Renin Inhibitors;
  • (8) Central Nervous System Agents;
  • (a) Analgesics and Antipyretics;
  • (A) Nonsteroidal Anti-inflammatory Agents;
  • (i) Cyclooxygenase-2 (COX-2) Inhibitors;
  • (ii) Salicylates;
  • (iii) Other Nonsteroidal Anti-inflammatory Agents;
  • (B) Opiate Agonists;
  • (C) Opiate Partial Agonists;
  • (D) Analgesics and Antipyretics, Miscellaneous;
  • (b) Opiate Antagonists;
  • (c) Anticonvulsants, does not include Barbiturates;
  • (A) Benzodiazepines;
  • (B) Hydantoins;
  • (C) Succinimides;
  • (D) Anticonvulsants, Miscellaneous;
  • (d) Psychotherapeutic Agents;
  • (A) Antidepressants;
  • (i) Monoamine Oxidase Inhibitors;
  • (ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;
  • (iii) Selective Serotonin- Reuptake Inhibitors;
  • (iv) Serotonin Modulators;
  • (v) Tricyclics and Other Norepinephrine-reuptake Inhibitors;
  • (vi) Antidepressants, Miscellaneous;
  • (B) Antipsychotics, to include only the following:
  • (i) Atypical antipsychotics;
  • (e) Anorexigenic Agents and Respiratory and Cerebral Stimulants;
  • (A)Amphetamines;
  • (B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous;
  • (f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;
  • (A) Benzodiazepines;
  • (B) Anxiolytics, Seditives, and Hypnotics; Miscellaneous;
  • (g) Antimanic Agents;
  • (h) Antimigraine Agents;
  • (A) Selective Serotonin Agonists;
  • (i) Antiparkinsonian Agents;
  • (A) Adamantanes;
  • (B) Anticholinergic Agents;
  • (C) Catechol-O-Methyltransferase (COMT) Inhibitors;
  • (D) Dopamine Precursors;
  • (E) Dopamine Receptor Agonists;
  • (i) Ergot-derivative Dopamine Receptor Agonists;
  • (ii) Non-ergot-derivative Dopamine Receptor Agonists;
  • (F) Monoamine Oxidase B Inhibitors;
  • (j) Central Nervous System Agents, Miscellaneous;
  • (9) Contraceptives (foams, devices);
  • (10) Diagnostic Agents;
  • (11) Disinfectants (for Agents used on objects other than skin);
  • (12) Electrolytic, Caloric, and Water Balance;
  • (a) Acidifying Agents;
  • (b) Alkalinizing Agents;
  • (c) Ammonia Detoxicants;
  • (d) Replacements Preparations;
  • (e) Ion-Removing Agents;
  • (A) Calcium-removing Agents;
  • (B) Potassium-removing Agents;
  • (C) Phosphate-removing Agents;
  • (D) Other Ion-removing Agents;
  • (f) Caloric Agents;
  • (g) Diuretics;
  • (A) Loop Diuretics;
  • (B) Osmotic Diuretics;
  • (C) Potassium-sparing Diuretics;
  • (D) Thiazide Diuretics;
  • (E) Thiazide-like Diuretics;
  • (F) Diuretics, Miscellaneous;
  • (h) Irrigation Solutions;
  • (i) Uricosuric Agents;
  • (13) Enzymes;
  • (14) Respiratory Tract Agents;
  • (a) Antihistamines;
  • (b) Antitussives;
  • (c) Anti-inflammatory Agents;
  • (A) Leukotriene Modifiers;
  • (B) Mast-cell Stabilizers;
  • (d) Expectorants;
  • (e) Pulmonary Surfactants;
  • (f) Respiratory Agents, Miscellaneous;
  • (15) Eye, Ear, Nose, and Throat (EENT) Preparations;
  • (a) Antiallergic Agents;
  • (b) Anti-infectives;
  • (A) Antibacterials;
  • (B) Antifungals;
  • (C) Antivirals;
  • (D) Anti-infectives, Miscellaneous;
  • (c) Anti-inflammatory Agents;
  • (A) Corticosteroids;
  • (B) Nonsteroidal Anti-inflammatory Agents;
  • (C) Anti-inflammatory Agents, Miscellaneous;
  • (d) Local Anesthetics;
  • (e) Mydriatics;
  • (f) Mouthwashes and Gargles;
  • (g) Vasoconstrictors;
  • (h) Antiglaucoma Agents;
  • (A) α-Adrenergic Agonists;
  • (B) β-Adrenergic Agents;
  • (C) Carbonic Anhydrase Inhibitors;
  • (D) Miotics;
  • (E) Prostaglandin Analogs;
  • (i) EENT Drugs, Miscellaneous;
  • (16) Gastrointestinal Drugs;
  • (a) Antacids and Adsorbents;
  • (b) Antidiarrhea Agents;
  • (c) Antiflatulents;
  • (d) Cathartics and Laxatives;
  • (e) Cholelitholytic Agents;
  • (f) Emetics;
  • (g) Antiemetics;
  • (A) Antihistamines;
  • (B) 5-HT3 Receptor Antagonists;
  • (C) Antiemetics, Miscellaneous;
  • (h) Antiulcer Agents and Acid Suppressants;
  • (A) Histamine H2-Antogonists;
  • (B) Prostaglandins;
  • (C) Protectants;
  • (D) Proton-pump Inhibitors;
  • (i) Prokinetic Agents;
  • (j) Anti-inflammatory Agents;
  • (k) GI Drugs, Miscellaneous;
  • (17) Gold Compounds;
  • (18) Heavy Metal Antagonists;
  • NOTE: IV administration requires education and training compliance with 850-060-0212.
  • (19) Hormones and Synthetic Substitutes;
  • (a) Adrenals;
  • (b) Androgens;
  • (c) Contraceptives;
  • (d) Estrogens and Antiestrogens;
  • (A) Estrogens;
  • (B) Estrogen Agonists-Antiagonists;
  • (e) Gonadotropins;
  • (f) Antidiabetic Agents;
  • (A) α-Glucosidase Inhibitors;
  • (B) Amylinomimetics;
  • (C) Biguanides;
  • (D) Dipeptidyl Peptidase (DDP-4) Inhibitors;
  • (E) Incretin Mimetics;
  • (F) Insulins;
  • (G) Meglitinides;
  • (H) Sulfonylureas;
  • (I) Thiazolidinediones;
  • (g) Antihypoglycemic Agents;
  • (A) Glycogenolytic Agents;
  • (h) Parathyroid;
  • (i) Pituitary;
  • (j) Somatotropin Agonists and Antagonists;
  • (A) Somatotropin Agonists;
  • (B) Somatotropin Antagonists;
  • (k) Progestins;
  • (l) Thyroid and Antithyroid Agents;
  • (A) Thyroid Agents;
  • (B) Antithyroid Agents;
  • (20) Local Anesthetics;
  • (21) Oxytocics;
  • (22) Serums, Toxoids, and Vaccines;
  • (a) Serums;
  • (b) Toxoids;
  • (c) Vaccines;
  • (23) Skin and Mucous Membrane Agents;
  • (a) Anti-infectives;
  • (A) Antibacterials;
  • (B) Antivirals;
  • (C) Antifungals;
  • (i) Allylamines;
  • (ii) Azoles;
  • (iii) Benzylamines;
  • (iv) Hydroxypyridones;
  • (v) Polyenes;
  • (vi) Thiocarbamates;
  • (vii) Antifungals, Miscellaneous;
  • (D) Scabicides and Pediculicides;
  • (E) Local Anti-infectives, Miscellaneous;
  • (b) Anti-inflammatory Agents;
  • (c) Antipruritics and Local Anesthetics;
  • (d) Astringents;
  • (e) Cell Stimulants and Proliferants;
  • (f) Detergents;
  • (g) Emollients, Demulcents, and Protectants;
  • (h) Keratolytic Agents;
  • (i) Keratoplastic Agents;
  • (j) Depigmenting and Pigmenting Agents;
  • (A) Depigmenting Agents;
  • (B) Pigmenting Agents;
  • (k) Sunscreen Agents;
  • (l) Skin and Mucous Membrane Agents, Miscellaneous;
  • (24) Smooth Muscle Relaxants;
  • (a) Gastrointestinal Smooth Muscle Relaxants;
  • (b) Genitourinary Smooth Muscle Relaxants;
  • (c) Respiratory Smooth Muscle Relaxants;
  • (25) Vitamins;
  • (26) Miscellaneous Therapeutic Agents;
  • (a) Alcohol Deterrents limited to the following:
  • (A) Acamprosate;
  • (B) Disulfiram;
  • (C) Naltrexone
  • (b) 5-α Reductase Inhibitors;
  • (c) Antidotes;
  • (d) Antigout Agents;
  • (e) Biologic Response Modifiers, limited to Interferons;
  • (f) Bone Resorption Inhibitors;
  • (g) Cariostatic Agents;
  • (h) Complement Inhibitors;
  • (i) Disease-Modifying Antirheumatic Agents;
  • (j) Gonadotropin-releasing Hormone Antagonists;
  • (k) Immunosuppressive Agents;
  • (l) Other Miscellaneous Therapeutic Agents limited to the following:
  • (A) Alfuzosin Hydrochloride;
  • (B) Drotrecogin Alfa (Activated);
  • (C) Lanreoytide Acetate;
  • (D) Rilonacept;
  • (E) Sapropterin Dihydrochloride;
  • (F) Tamsulosin Hydrochloride.
  • Stat. Auth.: ORS 685.125
  • Stats. Implemented: ORS 685.145
  • Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11

Notes
1.) This online version of the OREGON BULLETIN is provided for convenience of reference and enhanced access. The official, record copy of this publication is contained in the original Administrative Orders and Rulemaking Notices filed with the Secretary of State, Archives Division. Discrepancies, if any, are satisfied in favor of the original versions. Use the OAR Revision Cumulative Index found in the Oregon Bulletin to access a numerical list of rulemaking actions after November 15, 2010.

2.) Copyright 2011 Oregon Secretary of State: Terms and Conditions of Use

Oregon Secretary of State • 136 State Capitol • Salem, OR 97310-0722
Phone: (503) 986-1523 • Fax: (503) 986-1616 • oregon.sos@state.or.us

© 2013 State of Oregon All Rights Reserved​